GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence

Reuters

2025/05/15

GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence

GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography (CBCT) images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510(k) clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium & Technologies (GEST) 2025 Annual Meeting in New York.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515250570) on May 15, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535844431"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535844431\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535844431?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535844431","market":"us","top_or_hot":-1,"title":"GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography (CBCT) images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510(k) clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium &amp; Technologies (GEST) 2025 Annual Meeting in New York.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515250570) on May 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-15 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography (CBCT) images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510(k) clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium &amp; Technologies (GEST) 2025 Annual Meeting in New York.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515250570) on May 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GEHC","symbol_name":"GE HEALTHCARE TECHNOLOGIES INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL5bW3Y8:1","article_id":"2535844431","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535844431","pubTimestamp":1747310579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography  images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510 clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium & Technologies  2025 Annual Meeting in New York.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GEHC":"GE HEALTHCARE TECHNOLOGIES INC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","BK4082":"医疗保健设备"},"translate_title":"GE HealthCare推出人工智能驱动的CleaRecon DL，用于增强3D成像，提高临床精度和信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GEHC":0.9},"content_text":"GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence\n    \n\n        GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography (CBCT) images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510(k) clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium & Technologies (GEST) 2025 Annual Meeting in New York.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515250570) on May 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}